Johnson & Johnson stock gains focus after 73% PSA response rate
Published on 11/09/2026 at 13:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSJohnson & Johnson advances prostate cancer program
- The investigational bispecific combination targets KLK2 and PSMA to activate complementary T-cell signals.
- The Phase 3 KLK2-comPAS study is evaluating whether adding JNJ-9401 improves outcomes in metastatic castration-resistant prostate cancer.
- The early findings came from heavily pretreated patients and require confirmation in a larger study.
Johnson & Johnson reported new early clinical data on Sunday, November 8, showing activity from an investigational immunotherapy combination in advanced prostate cancer. The company said the results were presented at the Society for Immunotherapy of Cancer 2026 Annual Meeting and support further development of pasritamig with JNJ-9401.
At the recommended regimen in the Phase 1 study, 11 of 15 patients achieved a reduction of at least 50 percent in prostate-specific antigen, or PSA. Seven patients, equal to 47 percent of the group, recorded reductions of at least 90 percent, while four reached undetectable PSA levels. All seven patients with reductions of at least 90 percent remained on treatment for more than six months without disease progression.
Early signals support larger trial
The combination uses two bispecific antibodies aimed at complementary immune signals. Pasritamig targets KLK2 and is designed to direct T cells toward prostate cancer cells, while JNJ-9401 targets PSMA and is intended to strengthen T-cell activation.
The findings came from a small subgroup of heavily pretreated patients, who had received a median of four previous lines of systemic therapy. Johnson & Johnson said no Grade 3 or higher treatment-related adverse events, dose-limiting toxicities, treatment-related discontinuations or treatment-related deaths were reported at the recommended regimen. Cytokine release syndrome occurred in three patients, all at Grade 1, and no cases of immune effector cell-associated neurotoxicity syndrome were reported.
The recommended schedule combines subcutaneous JNJ-9401 every six weeks with intravenous pasritamig every six weeks after two initial weekly step-up doses. The company said the schedule could support outpatient treatment, but the preliminary results do not establish clinical benefit or long-term safety.
The ongoing Phase 3 KLK2-comPAS study is testing pasritamig with or without JNJ-9401 in metastatic castration-resistant prostate cancer. For Johnson & Johnson, the program adds another potential growth driver to its oncology pipeline, although its commercial relevance remains dependent on confirmatory efficacy, safety and regulatory outcomes.
Johnson & Johnson stock traded at 249.73 euros on Lang & Schwarz at 13:31 CET on Monday, November 9, 1.87 percent above the Xetra close of Friday, November 6. The company source for the clinical update is Johnson & Johnson.
For investors, the next material readout will be progress in the Phase 3 program rather than the small Phase 1 subgroup itself. The evidence should therefore be viewed as an early pipeline signal, not as confirmation of a marketable treatment.
For the broader market context, see the S&P 500 market overview.
More news and analyses are available in the Johnson & Johnson stock topic.
Access the real-time quote of Johnson & Johnson stock.
Johnson & Johnson stock facts
- Company: Johnson & Johnson
- ISIN: US4781601046
- Ticker: JNJ
- Home exchange: NYSE
- Lang & Schwarz quote: 249.73 euros, Monday, November 9, 2026, 13:31 CET
- Daily comparison: 1.87 percent above the Xetra close of 245.15 euros from Friday, November 6, 2026
- Clinical program: Pasritamig plus JNJ-9401 in metastatic castration-resistant prostate cancer
